Form 4: Zevra Therapeutics Director Granted Stock Options

Zevra Therapeutics, Inc. reports the grant of 30,000 stock options to Director Thomas Anderson as compensation for board service.

Summary

• Thomas Anderson, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options on June 4, 2026.
• The stock options have an exercise price of $11.17 per share, equivalent to the closing stock price on the grant date.
• These options are part of the company's compensation policy for non-employee directors.
• Vesting of the options is scheduled for the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately prior to a change in control, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard director compensation event without providing new financial or strategic information.

Positives

• Director compensation aligns with company stock value at the time of grant.
• Incentive aligns director's interests with shareholders through stock options.
• Clear vesting schedule tied to continued service and corporate events.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the stock options is subject to market fluctuations and the company's future stock performance.
• Continued service is a condition for vesting, meaning the director could forfeit options if they leave the board before the vesting date.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely details a stock option grant.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to attract and retain experienced board members by aligning their compensation with the company's long-term performance and shareholder value.

Corporate Governance

Related Party Transactions

• Grant of 30,000 stock options to Director Thomas Anderson as compensation for his board service.

Stakeholder Impact

• Shareholders: The grant of options does not immediately dilute share count but represents potential future dilution if exercised. It aligns director incentives with shareholder interests.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.

Next Steps

• Monitoring the vesting of the stock options based on continued service and corporate events.
• Observing the company's stock performance relative to the option exercise price.

Key Dates

Keywords

Zevra Therapeutics, ZVRA, Form 4, Stock Options, Director Compensation, Securities, Insider Trading, Grant Date, Vesting Schedule